Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2004 Dec;1(3):259–267. doi: 10.1093/ecam/neh043

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2004, the authors Evidenced-based Complementary and Alternative Medicine, Vol. 1, Issue 3 © Oxford University Press 2004; all rights reserved. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.

PMC Copyright notice

Anti-CD14 and anti-TLR4 monoclonal antibodies neutralized the IL-12-inducing effect of ABH. (A) PBMCs were pre-incubated with anti-CD14, anti-TLR4, anti-TLR2 or control monoclonal antibody at four different doses (1000, 100, 10, 1 ng). Agaricus blazei extract was added after 4 h and incubation was continued for 16 h. IL-12 p40 in supernatants was quantified by ELISA. Data from three independent donors are shown. (B) Cells pre-treated with 1 μg of control monoclonal antibody (b), 1 μg of anti-CD14 antibody (c) or 1 μg of anti-TLR4 antibody (d) were stimulated with ABH for 16 h (b–d). Then, IL-12-producing cells were quantified by flow cytometry. Unstimulated PBMCs (a) were included as controls. Data shown are representative of three independent experiments.